We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Aduhelm’s Coverage Decision Leaves a Path for Other Investigational Antiamyloid Antibodies
Aduhelm’s Coverage Decision Leaves a Path for Other Investigational Antiamyloid Antibodies
Last week’s Aduhelm coverage decision by the Centers for Medicare and Medicaid Services (CMS) raises the bar for three other antiamyloid antibodies in late-stage development: Eisai’s and Biogen’s lecanemab, Eli Lilly’s donanemab and Roche’s gantenerumab. It all depends on the evidence that the drugmakers provide in their submissions to the FDA.